RT Journal Article SR Electronic T1 Phenylethylmalonamide in essential tremor. A double-blind controlled study. JF Journal of Neurology, Neurosurgery & Psychiatry JO J Neurol Neurosurg Psychiatry FD BMJ Publishing Group Ltd SP 932 OP 934 DO 10.1136/jnnp.44.10.932 VO 44 IS 10 A1 S Calzetti A1 L J Findley A1 F Pisani A1 A Richens YR 1981 UL http://jnnp.bmj.com/content/44/10/932.abstract AB A randomised double-blind placebo-controlled trial of phenylethylmalonamide, the major metabolite of primidone was performed in eight patients with essential tremor. Phenylethylmalonamide was given in a daily dose of 400 mg for one week and 800 mg for a second week. The compound had no statistically significant effect on the amplitude of tremor assessed by an accelerometric method, tests of performance, clinical evaluation and patient self assessment. No side effects occurred. Serum levels of phenylethylmalonamide on a daily dose of 400 mg were 11-27 micrograms/ml and on 800 mg daily were 16-48.5 micrograms/ml.